Analytical Testing

Novo Holdings to Acquire Catalent

Catalent, Inc., a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, recently announced they….

SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Putting Customers First

Contributor Cindy H. Dubin speaks with several leading CDMOs from around the globe on their unique development and manufacturing capabilities and technologies, and presents real-world examples of how they have put these to use to produce innovative compounds, lower development costs, and shorten time to market.

DRUG DEVELOPMENT - Overcoming Challenges on the Path From Candidate Selection to First-in-Human Clinical Testing

Eleanor Row, PhD, explores the current challenges drug developers face in transitioning their candidate molecules to first-in-human (FIH) clinical trials, including what the different drug development functions should be considering at this stage, and how an integrated approach can help to accelerate your molecule’s pathway to trial and beyond.

Frequently Asked Questions About Analytical Testing

What are the latest trends in analytical testing for pharmaceuticals?

Recent trends include advanced automation in lab processes, predictive in silico modeling, and the adoption of diverse analytical techniques to support evolving biologics, inhaled therapies, and personalized medicines.

How are CDMOs improving resilience in analytical supply chains?

CDMOs are using multi-sourcing strategies, expanding vendor bases, and implementing flexible automation solutions to mitigate risks related to material shortages, tariffs, and geopolitical disruptions.

What role does automation play in modern analytical labs?

Automation solutions—such as semi-automated inhaled product testing and plug‑and‑play instruments—are enhancing accuracy, efficiency, and agility in testing workflows.